Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data

Table 4 Association between microRNA-144-3p expression and clinicopathological parameters in non-small cell lung cancer, based on The Cancer Genome Atlas data

Clinicopathological feature		n	mean ± SD	p-value
Tissue	Adjacent non-cancerous tissue	87	5.4243 ± 1.4702	< 0.001^*
Tissue	LUSC+LUAD	777	2.8632 ± 1.37928	< 0.001^*
Age (years)	< 60	179	2.919 ± 1.37944	0.330
Age (years)	≥60	573	2.8038 ± 1.37438	0.330
Gender	Female	323	2.8799 ± 1.37826	0.776
Gender	Male	454	2.8513 ± 1.38139	0.776
Tumor location	Central lung	160	2.6915 ± 1.24372	0.604
Tumor location	Peripheral lung	186	2.7666 ± 1.41787	0.604
Stage	Stage I-II	625	2.8494 ± 1.3589	0.630
Stage	Stage III-IV	144	2.9145 ± 1.47731	0.630
T	T1-T2	647	2.9128 ± 1.37596	0.008^*
T	T3-T4	127	2.5658 ± 1.33528	0.008^*
N	No	504	2.8585 ± 1.39145	0.803
N	Yes	258	2.8324 ± 1.35039	0.803
M	No	535	2.7722 ± 1.34822	0.124
M	Yes	22	3.277 ± 1.45564	0.124

SD Standard deviation, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma
^*p < 0.05 was considered statistically significant

ISSN: 1465-993X